Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients - PubMed (original) (raw)
Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients
E P Sampaio et al. J Exp Med. 1992.
Abstract
10 patients with borderline and lepromatous leprosy were selected for a prolonged trial with recombinant interferon gamma (rIFN-gamma). Patients received 30 micrograms intradermally for six injections over a 9-d period, and then either 100 micrograms intradermally every 1 mo for 10 mo or every 2 wk for 5 mo (total, 1.2 mg). Erythema nodosum leprosum (ENL) was induced in 60% of the patients within 6-7 mo, as compared with an incidence of 15% per year with multiple drug therapy alone. The mean whole-body reduction in bacterial index over the first 6 mo was 0.9 log units. Cutaneous induration at the intradermal injection sites of greater than or equal to 15 mm predicted the development of a subsequent reactional state. Monocytes obtained from patients receiving the lymphokine demonstrated an increased respiratory burst and a 2.5-5.1-fold increase in tumor necrosis factor alpha (TNF-alpha) secretion in response to agonists. Patients in ENL had an even higher release of TNF-alpha from monocytes as well as high levels of TNF-alpha in the plasma (mean, 2,000 pg/ml). Thalidomide therapy was required to treat the systemic manifestations of ENL. Control of toxic symptoms with thalidomide was associated with a 50-80% reduction in agonist-stimulated monocyte TNF-alpha secretion. IFN-gamma enhanced the monocyte release of TNF-alpha by 3-7.5-fold (agonist dependent) when added to patient's cells in vitro, and this could be suppressed by the in vitro addition of 10 micrograms/ml of thalidomide.
Similar articles
- The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.
Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. Sampaio EP, et al. J Infect Dis. 1993 Aug;168(2):408-14. doi: 10.1093/infdis/168.2.408. J Infect Dis. 1993. PMID: 8335978 - Thalidomide in the treatment of leprosy.
Teo S, Resztak KE, Scheffler MA, Kook KA, Zeldis JB, Stirling DI, Thomas SD. Teo S, et al. Microbes Infect. 2002 Sep;4(11):1193-202. doi: 10.1016/s1286-4579(02)01645-3. Microbes Infect. 2002. PMID: 12361920 Review. - Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Sampaio EP, Malta AM, Sarno EN, Kaplan G. Sampaio EP, et al. Int J Lepr Other Mycobact Dis. 1996 Sep;64(3):268-73. Int J Lepr Other Mycobact Dis. 1996. PMID: 8862260 Clinical Trial. - IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, Gomez-Melgar M, Saul A, Estrada-Parra S, Estrada-Garcia I. Partida-Sanchez S, et al. Int Arch Allergy Immunol. 1998 May;116(1):60-6. doi: 10.1159/000023926. Int Arch Allergy Immunol. 1998. PMID: 9623511 Clinical Trial. - The role of thalidomide in the management of erythema nodosum leprosum.
Walker SL, Waters MF, Lockwood DN. Walker SL, et al. Lepr Rev. 2007 Sep;78(3):197-215. Lepr Rev. 2007. PMID: 18035771 Review.
Cited by
- Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early wallerian degeneration.
Schröder JM, Sellhaus B, Wöhrmann T, Kögel B, Zwingenberger K. Schröder JM, et al. Acta Neuropathol. 1995;89(5):415-9. doi: 10.1007/BF00307645. Acta Neuropathol. 1995. PMID: 7618439 - Cytokine production at the site of disease in human tuberculosis.
Barnes PF, Lu S, Abrams JS, Wang E, Yamamura M, Modlin RL. Barnes PF, et al. Infect Immun. 1993 Aug;61(8):3482-9. doi: 10.1128/iai.61.8.3482-3489.1993. Infect Immun. 1993. PMID: 8335379 Free PMC article. - The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression.
de Souza Sales J, Lara FA, Amadeu TP, de Oliveira Fulco T, da Costa Nery JA, Sampaio EP, Pinheiro RO, Sarno EN. de Souza Sales J, et al. Clin Exp Immunol. 2011 Aug;165(2):251-63. doi: 10.1111/j.1365-2249.2011.04412.x. Epub 2011 May 18. Clin Exp Immunol. 2011. PMID: 21592112 Free PMC article. - Cellular immune response to Mycobacterium leprae infection in human immunodeficiency virus-infected individuals.
Sampaio EP, Caneshi JR, Nery JA, Duppre NC, Pereira GM, Vieira LM, Moreira AL, Kaplan G, Sarno EN. Sampaio EP, et al. Infect Immun. 1995 May;63(5):1848-54. doi: 10.1128/iai.63.5.1848-1854.1995. Infect Immun. 1995. PMID: 7729894 Free PMC article. - Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.
Raman VS, O'Donnell J, Bailor HR, Goto W, Lahiri R, Gillis TP, Reed SG, Duthie MS. Raman VS, et al. Infect Immun. 2009 Dec;77(12):5623-30. doi: 10.1128/IAI.00508-09. Epub 2009 Sep 28. Infect Immun. 2009. PMID: 19786561 Free PMC article.
References
- Clin Exp Immunol. 1991 Apr;84(1):103-8 - PubMed
- J Exp Med. 1985 Jun 1;161(6):1503-12 - PubMed
- J Exp Med. 1991 Mar 1;173(3):699-703 - PubMed
- J Exp Med. 1990 Nov 1;172(5):1509-12 - PubMed
- Blood. 1990 Oct 1;76(7):1405-9 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources